Twist Bioscience Co. (NASDAQ:TWST) COO Sells $140,400.75 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,845 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $140,400.75. Following the sale, the chief operating officer now directly owns 269,199 shares of the company’s stock, valued at approximately $13,284,970.65. This trade represents a 1.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Thursday, January 23rd, Patrick John Finn sold 2,422 shares of Twist Bioscience stock. The stock was sold at an average price of $50.17, for a total transaction of $121,511.74.
• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00.

Twist Bioscience Trading Up 3.2 %

NASDAQ TWST traded up $1.64 during mid-day trading on Wednesday, reaching $53.66. 942,522 shares of the company’s stock traded hands, compared to its average volume of 780,335. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a fifty day simple moving average of $48.63 and a 200-day simple moving average of $46.21. The company has a market cap of $3.19 billion, a price-to-earnings ratio of -14.91 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business’s revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.75) EPS. Equities research analysts forecast that Twist Bioscience Co. will post -2.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC boosted its position in shares of Twist Bioscience by 83.9% in the second quarter. AQR Capital Management LLC now owns 61,428 shares of the company’s stock worth $3,027,000 after buying an additional 28,027 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Twist Bioscience by 3.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company’s stock worth $1,531,000 after purchasing an additional 1,104 shares during the last quarter. SG Americas Securities LLC raised its holdings in Twist Bioscience by 407.1% in the 3rd quarter. SG Americas Securities LLC now owns 10,958 shares of the company’s stock valued at $495,000 after acquiring an additional 8,797 shares in the last quarter. CWM LLC raised its holdings in Twist Bioscience by 141.9% in the 3rd quarter. CWM LLC now owns 5,894 shares of the company’s stock valued at $266,000 after acquiring an additional 3,457 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Twist Bioscience by 30.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company’s stock worth $910,000 after buying an additional 4,661 shares in the last quarter.

Analysts Set New Price Targets

TWST has been the topic of a number of analyst reports. Scotiabank raised their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. TD Cowen reaffirmed a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Robert W. Baird raised their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.